These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 19384690)

  • 1. Optimal two-stage randomized multinomial designs for Phase II oncology trials.
    Sun LZ; Chen C; Patel K
    J Biopharm Stat; 2009; 19(3):485-93. PubMed ID: 19384690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An efficient algorithm to determine the optimal two-stage randomized multinomial designs in oncology clinical trials.
    Zhang Y; Mietlowski W; Chen B; Wang Y
    J Biopharm Stat; 2011 Jan; 21(1):56-65. PubMed ID: 21191854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A two-stage phase II trial design utilizing both primary and secondary endpoints.
    Lin X; Allred R; Andrews G
    Pharm Stat; 2008; 7(2):88-92. PubMed ID: 17252536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
    Jenkins M; Stone A; Jennison C
    Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal designs for two-arm, phase II clinical trial design with multiple constraints.
    Mayo MS; Mahnken JD; Soong SJ
    J Biopharm Stat; 2010 Jan; 20(1):106-24. PubMed ID: 20077252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II trials with a prospective control.
    Jung SH
    Stat Med; 2008 Feb; 27(4):568-83. PubMed ID: 17573688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exact two-stage designs for phase II activity trials with rank-based endpoints.
    Wilding GE; Shan G; Hutson AD
    Contemp Clin Trials; 2012 Mar; 33(2):332-41. PubMed ID: 22074983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing randomized phase II trials assessing tumor progression.
    Stone A; Wheeler C; Carroll K; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized two-stage Phase II clinical trial designs based on Barnard's exact test.
    Shan G; Ma C; Hutson AD; Wilding GE
    J Biopharm Stat; 2013; 23(5):1081-90. PubMed ID: 23957517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trial design for evaluation of novel targeted therapies.
    Farley J; Rose PG
    Gynecol Oncol; 2010 Feb; 116(2):173-6. PubMed ID: 19853899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testing the wrong hypothesis in phase II oncology trials: there is a better alternative.
    Ratain MJ; Karrison TG
    Clin Cancer Res; 2007 Feb; 13(3):781-2. PubMed ID: 17289865
    [No Abstract]   [Full Text] [Related]  

  • 14. Curtailed two-stage designs with two dependent binary endpoints.
    Chen CM; Chi Y
    Pharm Stat; 2012; 11(1):57-62. PubMed ID: 22162348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
    Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
    [No Abstract]   [Full Text] [Related]  

  • 16. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-stage k-sample designs for the ordered alternative problem.
    Shan G; Hutson AD; Wilding GE
    Pharm Stat; 2012; 11(4):287-94. PubMed ID: 22408050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newer phase II trial designs gaining ground.
    Benowitz S
    J Natl Cancer Inst; 2007 Oct; 99(19):1428-9. PubMed ID: 17895467
    [No Abstract]   [Full Text] [Related]  

  • 19. Novel designs and end points for phase II clinical trials.
    Adjei AA; Christian M; Ivy P
    Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of secondary endpoints in two-stage phase II oncology trials.
    Kunz CU; Kieser M
    Stat Med; 2012 Dec; 31(30):4352-68. PubMed ID: 22930470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.